Table 1.
MCC patient baseline characteristics.
| All Patients n=60 |
PIK3CA Mutational Status | MCPyV Status* | |||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Positive n=7 | Negative n=53 | P value | Positive n=38 | Negative n=20 | P value | ||
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |||
| Age, yrs | 0.326 | 0.615 | |||||
| Median | 73 | 68 | 77 | 73.5 | 71 | ||
| Range | 44-94 | 59-89 | 44-94 | 44-90 | 52-94 | ||
|
| |||||||
| Sex | 0.040 | <0.001 | |||||
| Male | 38 (63) | 7 (100) | 31 (58) | 18 (47) | 19 (95) | ||
| Female | 22 (37) | 0 (0) | 22 (42) | 20 (53) | 1 (5) | ||
|
| |||||||
| Immunosuppression | 1.000 | 1.000 | |||||
| Yes | 8 (13) | 1 (14) | 7 (13) | 5 (13) | 3 (15) | ||
| No | 52 (87) | 6 (86) | 46 (87) | 33 (87) | 17 (85) | ||
|
| |||||||
| Stage | 0.176# | 0.016## | |||||
| I | 15 (25) | 0 (0) | 15 (28) | 12 (32) | 3 (15) | ||
| II | 13 (22) | 2 (29) | 11 (21) | 9 (24) | 4 (20) | ||
| III | 23 (38) | 3 (43) | 20 (38) | 15 (39) | 7 (35) | ||
| IV | 9 (15) | 2 (29) | 7 (13) | 2 (5) | 6 (30) | ||
|
| |||||||
| Lymph Nodes | 0.432 | 0.174 | |||||
| Involved | 32 (53) | 5 (71) | 27 (51) | 17 (45) | 13 (65) | ||
| None | 28 (47) | 2 (29) | 26 (49) | 21 (55) | 7 (35) | ||
|
| |||||||
| Primary Tumor | 0.748 | 0.111 | |||||
| Head & Neck | 27 (45) | 3 (43) | 24 (45) | 15 (39) | 11 (55) | ||
| Extremity | 21 (35) | 1 (14) | 20 (38) | 17 (45) | 3 (15) | ||
| Trunk | 5 (8) | 0 (0) | 5 (9) | 3 (8) | 2 (10) | ||
| unknown | 7 (12) | 3 (43) | 4 (8) | 3 (8) | 4 (20) | ||
|
| |||||||
| Margins | 1.000 | 0.530 | |||||
| Negative | 22 (37) | 3 (43) | 19 (36) | 16 (42) | 6 (30) | ||
| Close | 12 (20) | 2 (29) | 10 (19) | 8 (21) | 4 (20) | ||
| Positive | 11 (18) | 1 (14) | 10 (19) | 6 (16) | 5 (25) | ||
| unknown | 15 (25) | 1 (14) | 14 (26) | 8 (21) | 5 (25) | ||
*
due to limited amount of tumor, we were unable to determine MCPyV status for two cases
#
Stage I vs. II-IV;
##
Stage I-III vs. IV